Brepocitinib Overview & RVT-3101 Update
Roivant Has Potential Category Winners in 5 out of 7 Leading I&I Markets and
is in Multiple Interesting Growth Areas as Well
2028 Top US I&I Markets¹
Additional Growth Markets
Psoriasis
$22.3 billion
CIDP
~16K US Patients
Atopic Dermatitis
$12.2 billion
Myasthenia Gravis
~59K US Cases
Crohn's Disease
$9.3 billion
Thyroid Eye Disease
~15-20K New US Cases/Year
Ulcerative Colitis
$6.9 billion
Graves' Disease
~116K US Incident Pop.
SLE
$3.8 billion
Dermatomyositis
~37K US Adults
Rheumatoid Arthritis
$10.2 billion
Psoriatic Arthritis
$3.9 billion
roivant
Indications with active development programs
Other than VTAMA in psoriasis, drugs are investigational and subject to regulatory approval.
1. Source: Evaluate Pharma.
Other indications
6
For investor audiences onlyView entire presentation